Prophylactic and therapeutic inhibition of allergic airway inflammation by probiotic Escherichia coli O83

Oral supplementation with probiotic bacteria is a promising alternative for allergy prevention. However, a recent meta-analysis has demonstrated that orally delivered bacteria only prevented the development of certain allergic manifestations, such as atopic eczema, but had limited efficacy on respiratory allergies.1 Similarly, oral delivery of the gram-negative probiotic bacterial strain Escherichia coli A0 34/86 (E coli O83; serotype O83:K24:H31; a commercially available oral live vaccine, Colinfant Newborn) to high-risk infants reduced development of atopic diseases in later life but had no beneficial effects on respiratory allergies.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Letter to the Editor Source Type: research